Literature DB >> 23132820

Cell surface structures influence lung clearance rate of systemically infused mesenchymal stromal cells.

Johanna Nystedt1, Heidi Anderson, Jonne Tikkanen, Mika Pietilä, Tia Hirvonen, Reijo Takalo, Annamari Heiskanen, Tero Satomaa, Suvi Natunen, Siri Lehtonen, Tanja Hakkarainen, Matti Korhonen, Saara Laitinen, Leena Valmu, Petri Lehenkari.   

Abstract

The promising clinical effects of mesenchymal stromal/stem cells (MSCs) rely especially on paracrine and nonimmunogenic mechanisms. Delivery routes are essential for the efficacy of cell therapy and systemic delivery by infusion is the obvious goal for many forms of MSC therapy. Lung adhesion of MSCs might, however, be a major obstacle yet to overcome. Current knowledge does not allow us to make sound conclusions whether MSC lung entrapment is harmful or beneficial, and thus we wanted to explore MSC lung adhesion in greater detail. We found a striking difference in the lung clearance rate of systemically infused MSCs derived from two different clinical sources, namely bone marrow (BM-MSCs) and umbilical cord blood (UCB-MSCs). The BM-MSCs and UCB-MSCs used in this study differed in cell size, but our results also indicated other mechanisms behind the lung adherence. A detailed analysis of the cell surface profiles revealed differences in the expression of relevant adhesion molecules. The UCB-MSCs had higher expression levels of α4 integrin (CD49d, VLA-4), α6 integrin (CD49f, VLA-6), and the hepatocyte growth factor receptor (c-Met) and a higher general fucosylation level. Strikingly, the level of CD49d and CD49f expression could be functionally linked with the lung clearance rate. Additionally, we saw a possible link between MSC lung adherence and higher fibronectin expression and we show that the expression of fibronectin increases with MSC culture confluence. Future studies should aim at developing methods of transiently modifying the cell surface structures in order to improve the delivery of therapeutic cells.
Copyright © 2012 AlphaMed Press.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23132820     DOI: 10.1002/stem.1271

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  44 in total

Review 1.  Concise review: mesoangioblast and mesenchymal stem cell therapy for muscular dystrophy: progress, challenges, and future directions.

Authors:  Suzanne E Berry
Journal:  Stem Cells Transl Med       Date:  2014-11-12       Impact factor: 6.940

2.  Transient proteolytic modification of mesenchymal stromal cells increases lung clearance rate and targeting to injured tissue.

Authors:  Erja Kerkelä; Tanja Hakkarainen; Tuomas Mäkelä; Mari Raki; Oleg Kambur; Lotta Kilpinen; Janne Nikkilä; Siri Lehtonen; Ilja Ritamo; Roni Pernu; Mika Pietilä; Reijo Takalo; Tatu Juvonen; Kim Bergström; Eija Kalso; Leena Valmu; Saara Laitinen; Petri Lehenkari; Johanna Nystedt
Journal:  Stem Cells Transl Med       Date:  2013-06-03       Impact factor: 6.940

Review 3.  Stem cells, cell therapies, and bioengineering in lung biology and diseases. Comprehensive review of the recent literature 2010-2012.

Authors:  Daniel J Weiss
Journal:  Ann Am Thorac Soc       Date:  2013-10

Review 4.  In vitro augmentation of mesenchymal stem cells viability in stressful microenvironments : In vitro augmentation of mesenchymal stem cells viability.

Authors:  Fatemeh Amiri; Ali Jahanian-Najafabadi; Mehryar Habibi Roudkenar
Journal:  Cell Stress Chaperones       Date:  2014-12-20       Impact factor: 3.667

Review 5.  Cell Therapy for Ischemic Stroke: How to Turn a Promising Preclinical Research into a Successful Clinical Story.

Authors:  Gabrielle Mangin; Nathalie Kubis
Journal:  Stem Cell Rev Rep       Date:  2019-04       Impact factor: 5.739

Review 6.  Role of mesenchymal stem cells in cell life and their signaling.

Authors:  Shihori Tanabe
Journal:  World J Stem Cells       Date:  2014-01-26       Impact factor: 5.326

Review 7.  The Role of Integrin α6 (CD49f) in Stem Cells: More than a Conserved Biomarker.

Authors:  Paul H Krebsbach; Luis G Villa-Diaz
Journal:  Stem Cells Dev       Date:  2017-06-12       Impact factor: 3.272

8.  Very late antigen-5 facilitates stromal progenitor cell differentiation into myofibroblast.

Authors:  Namita Sen; Mark Weingarten; Yakov Peter
Journal:  Stem Cells Transl Med       Date:  2014-10-01       Impact factor: 6.940

Review 9.  Practical Issues with the Use of Stem Cells for Cancer Gene Therapy.

Authors:  Faranak Salman Nouri; Debabrata Banerjee; Arash Hatefi
Journal:  Stem Cell Rev Rep       Date:  2015-10       Impact factor: 5.739

Review 10.  Cell-based therapy for ischemic stroke.

Authors:  Jing Zhang; Michael Chopp
Journal:  Expert Opin Biol Ther       Date:  2013-06-06       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.